Therapeutic Choices for Patients With HR-Positive, HER2-Low Breast Cancer

Dato-DXd Shows Tolerability Vs Chemo in HER2- Metastatic Breast Cancer

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPION-Breast01 trial. This is the second of 2 parts from this event.

Treatment With ADCs Advances in Endocrine-Refractory Breast Cancer

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPiCS-02 trial.

Yan Emphasizes Use of Supportive Care With Dato-DXd in Breast Cancer

During a live event, Fengting Yan, MD, PhD, discussed safety outcomes from the TROPION-Breast01 and supportive care for datopotamab deruxtecan in metastatic breast cancer.

Sequencing and AEs Guide Next Steps for Dato-DXd in Breast Cancer

Virginia G. Kaklamani, MD, DSc, discusses datopotamab deruxtecan and other antibody-drug conjugates available for patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer.

Antibody-Drug Conjugates Show Unique Advantage in Breast Cancer

Erika P. Hamilton, MD, discusses antibody-drug conjugates in multiple types of breast cancer, and when to use these drugs in sequence.

Type of Breast Cancer in TROPION-PanTumor01 Affects Level of Benefit

Erika P. Hamilton, MD, discusses the patient population with breast cancer enrolled in the TROPION-PanTumor01 trial in relation to the efficacy of datopotamab deruxtecan.

PFS Provides Rationale for Dato-DXd vs Chemo in HR+, HER2– Breast Cancer

Christos Vaklavas, MD, discusses the results of the TROPION-Breast01 trial of datopotamab deruxtecan in patients with metastatic breast cancer.

ADCs Demonstrate Superiority Vs Chemotherapy in Recurrent Breast Cancer

During a Case-Based Roundtable® event, Reshma Mahtani, DO, discussed the importance of data from the TROPiCS-02 and TROPION-Breast01 trials of antibody-drug conjugates in patients with hormone receptor positive metastatic breast cancer.

Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC

During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.

Datopotamab Shows Benefit in HER2– and HER2-Low Breast Cancer

During a Case-Based Roundtable® event, Timothy J. Pluard, MD, explores datopotamab deruxtecan as an option in hormone receptor–positive, HER2-negative breast cancer in the second article of a 2-part series.

Pluard Discusses Dosing of ADCs in HR+, HER2- Breast Cancer

During a Case-Based Roundtable® event, Timothy J. Pluard, MD, discussed the use of sacituzumab govitecan advanced breast cancer as well as dosing considerations in the first article of a 2-part series.

Incorporating Datopotamab Deruxtecan in Advanced Breast Cancer

During a Case-Based Roundtable® event, Virginia G. Kaklamani, MD, discussed the use of datopotamab deruxtecan in patients with advanced breast cancer and how next-generation sequencing plays an important role in their treatment in the second article of a 2-part series.

Analyzing ADC Treatment Sequencing in Advanced Breast Cancer

In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.